Technology
Health
Pharmaceutical

MEI Pharma

$3.03
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.02 (0.50%) Today
+$0.02 (0.50%) Today

Why Robinhood?

You can buy or sell MEI Pharma and other stocks, options, ETFs, and crypto commission-free!

About

MEI Pharma, Inc. engages in the clinical development of novel therapies for cancer. Its drug candidates includes Pracinostat, an oral HDAC inhibitor that is being developed in combination with azacitidine for the treatment of acute myeloid leukemia and myelodysplastic syndrome. Read More Its pipeline also consists of ME-401, a highly selective, oral PI3K delta inhibitor; voruciclib, an oral, selective CDK inhibitor; and ME-344, a novel mitochondrial inhibitor. The company was founded on December 1, 2000 and is headquartered in San Diego, CA.

Employees
32
Headquarters
San Diego, California
Founded
2000
Market Cap
214.10M
Price-Earnings Ratio
β€”
Dividend Yield
β€”
Average Volume
340.47K
High Today
$3.10
Low Today
$3.01
Open Price
$3.01
Volume
5.68K
52 Week High
$5.14
52 Week Low
$1.82

Collections

Technology
Health
Pharmaceutical
Medical
Cancer Prevention
US
North America

News

MarketBeatMar 3

Stock Price, News, & Analysis for MEI Pharma

MEI Pharma, Inc., a pharmaceutical company, focuses on the clinical development of novel therapies for the treatment of cancer. The company's clinical drug candidate includes Pracinostat, an oral available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes ME-401, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with relapsed/refractory chronic lymphocyti...

19
Simply Wall StFeb 22

What Kind Of Investor Owns Most Of MEI Pharma, Inc. (NASDAQ:MEIP)?

Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! A look at the shareholders of MEI Pharma, Inc. (NASDAQ:MEIP) can tell us which group is most powerful. Large companies usually have institutions as shareholders, and we usually see insiders owning shares in smaller companies. I generally like to see some degree of insider ownership, even if only a little. As Nassim Nicholas Taleb said, β€˜Don’t tell me what you think, tell me what you have in your...

47

Earnings

-$0.36
-$0.16
$0.04
$0.24
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Estimated
β€”
Actual
Expected May 8, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.